Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

12.58 -0.65 (-4.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Janux Therapeutics Inc

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Winston Kung to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Janux Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.